Header Logo

Connection

Jeff Slezak to Neoplasm Staging

Back to Details
This is a "connection" page, showing publications Jeff Slezak has written about Neoplasm Staging.
Jeff Slezak
Connection Strength
0.503
Neoplasm Staging
  1. Risk factors for locoregional recurrence after mastectomy in stage T1 N0 breast cancer. Am J Clin Oncol. 2014 Oct; 37(5):486-91.
    View in: PubMed
    Score: 0.111
  2. Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. Cancer. 2006 Jun 15; 106(12):2630-5.
    View in: PubMed
    Score: 0.063
  3. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol. 2000 Nov; 164(5):1591-5.
    View in: PubMed
    Score: 0.042
  4. The effect of urologist experience on choosing active surveillance for prostate cancer. World J Urol. 2015 Nov; 33(11):1701-6.
    View in: PubMed
    Score: 0.029
  5. Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus 'X'. Radiat Oncol. 2014 Jul 29; 9:171.
    View in: PubMed
    Score: 0.027
  6. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int. 2008 Jan; 101(2):170-4.
    View in: PubMed
    Score: 0.017
  7. Histopathologic grading of adult medulloblastomas. Cancer. 2007 Jun 15; 109(12):2557-65.
    View in: PubMed
    Score: 0.017
  8. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. Cancer. 2006 Aug 01; 107(3):521-9.
    View in: PubMed
    Score: 0.016
  9. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol. 2005 Apr; 173(4):1121-5.
    View in: PubMed
    Score: 0.014
  10. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 2005 Apr; 95(6):751-6.
    View in: PubMed
    Score: 0.014
  11. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol. 2004 Oct; 172(4 Pt 1):1328-32.
    View in: PubMed
    Score: 0.014
  12. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol. 2003 Nov; 170(5):1872-6.
    View in: PubMed
    Score: 0.013
  13. Clinical significance of alterations of chromosome 8 detected by fluorescence in situ hybridization analysis in pathologic organ-confined prostate cancer. Genes Chromosomes Cancer. 2002 Aug; 34(4):363-71.
    View in: PubMed
    Score: 0.012
  14. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age. J Urol. 2002 Aug; 168(2):525-9.
    View in: PubMed
    Score: 0.012
  15. TBX2 is preferentially amplified in BRCA1- and BRCA2-related breast tumors. Cancer Res. 2002 Jul 01; 62(13):3587-91.
    View in: PubMed
    Score: 0.012
  16. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc. 2001 Jun; 76(6):576-81.
    View in: PubMed
    Score: 0.011
  17. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001 Apr; 165(4):1146-51.
    View in: PubMed
    Score: 0.011
  18. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. 2000 Jul; 164(1):101-5.
    View in: PubMed
    Score: 0.010
  19. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology. 1999 Sep; 54(3):479-85.
    View in: PubMed
    Score: 0.010
  20. Dedifferentiation in the metastatic progression of prostate carcinoma. Cancer. 1999 Aug 15; 86(4):657-63.
    View in: PubMed
    Score: 0.010
  21. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology. 1999 Jul; 54(1):105-10.
    View in: PubMed
    Score: 0.010
  22. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999 Apr; 161(4):1223-7; discussion 1227-8.
    View in: PubMed
    Score: 0.009
  23. Androgen receptor expression in prostatic intraepithelial neoplasia and cancer. J Urol. 1999 Apr; 161(4):1229-32.
    View in: PubMed
    Score: 0.009
  24. Preoperative androgen-deprivation therapy for clinical stage T3 prostate cancer. Semin Urol Oncol. 1997 Nov; 15(4):222-9.
    View in: PubMed
    Score: 0.009

© 2024 Kaiser Permanente